Irisin
FNDC5 Cleavage Product · Exercise Myokine
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
Irisin is a proposed FNDC5 cleavage myokine whose very existence and measurement in humans have been openly contested since Erickson's 2013 antibody critique and Albrecht et al. 2015 (Scientific Reports), which argued that commercial-ELISA irisin signals are largely artifacts of non-specific antibodies, with reported human values spanning roughly six orders of magnitude (40 pg/mL to 4.3 ug/mL). Antibody-free tandem mass spectrometry (Jedrychowski et al. 2015, Cell Metabolism) did detect circulating irisin at about 3 to 4 ng/mL and showed it rises with training, but the fat-browning and metabolic effects seen in rodents have, per the 2021 Endocrine Reviews synthesis, little or no support in humans, and there are no completed human intervention trials of irisin as a therapy, so the supported claim sits at animal and mechanistic level.
- FDA
- Not an FDA-approved drug and not a marketed supplement; exists only as a research reagent and preclinical target, with no completed human intervention trials.
- WADA
- Not listed on the WADA Prohibited List; irisin is an endogenous exercise-induced protein and no administered irisin product is in clinical use.
Reference only. Not medical advice.
What can go wrong
No human safety data for administered irisin; the larger scientific issue is that circulating human levels and effects are measurement-disputed, and no product exists to take.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Irisin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
An exercise-induced protein hormone from muscle that promotes fat-tissue browning, improves insulin sensitivity, and crosses the blood-brain barrier. Dubbed a "fountain of youth" protein in popular press.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Irisin is a hormone released by muscle during exercise, cleaved from a precursor protein called FNDC5, which is itself switched on by the exercise-activated regulator PGC1-alpha. Its claimed payoff is striking: irisin travels to white fat and "browns" it, turning energy-storing fat into heat-burning fat, which would raise energy expenditure, improve blood sugar and insulin sensitivity, and capture some of exercise’s metabolic benefits. It has also been proposed to act on bone, brain and heart. The catch is that how much of this actually happens at real human levels is genuinely disputed.
Irisin is a small myokine, a muscle-secreted hormone, cleaved from the larger precursor protein FNDC5. The pathway runs exercise to PGC1-alpha to FNDC5 to irisin. It exists as a research protein rather than a drug, and a recurring theme in its science is how hard it has been to detect and measure reliably, which is central to its story.
- Type
- Muscle myokine (from FNDC5)
- Trigger
- Exercise (PGC1-alpha)
- Claimed effect
- Browns white fat
- Human levels
- Very low
- Status
- Real but contested
- Approved product
- None
The "Exercise Hormone," Nearly A Myth
Irisin arrived in 2012 with enormous excitement, framed as the molecular basis of exercise’s fat-burning and metabolic benefits, almost exercise in a hormone. Then it was nearly debunked. Two problems hit hard. The human FNDC5 gene has an unusual mutated start codon, raising doubt about whether functional irisin is even made in people. And most measurements of irisin in blood relied on commercial antibody kits that turned out to cross-react with unrelated proteins, prompting a 2015 paper to bluntly call irisin a myth rather than an exercise-inducible myokine. It was then partly vindicated: more rigorous mass-spectrometry work confirmed that irisin does circulate in humans, but at very low levels. So irisin is real, yet its actual importance at physiological human levels, and any therapeutic value, remains genuinely unresolved, while the dramatic effects came from high recombinant doses in mice. The exercise-in-a-bottle marketing far outruns the science.
Safety in detail
There is no human intervention or safety trial of irisin as a therapy. Reported blood-level associations rest on ELISA methods whose specificity is contested, so both benefit claims and any 'normal range' should be treated as unsettled rather than established.
- There is no human safety data for irisin as a therapeutic, because no irisin drug or product exists.
- It is an endogenous hormone studied as a research protein, not an injected gray-market peptide.
- Boost-your-irisin supplement and exercise marketing is unvalidated.
- It is not a classic doping substance.
- The unresolved question of whether physiological human levels do anything meaningful means even its benefit is unproven.
Children and teenagers
Irisin has no therapeutic product and no role as a drug for minors. Boost-your-irisin marketing is unvalidated for anyone, and the reliable source of the benefits attributed to it, exercise, is what genuinely helps children. There is no appropriate pediatric drug use.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Irisin has no approved product, so its economy is mostly one of hype: supplements and programs marketed as ways to boost your irisin, recombinant irisin sold as a research reagent, and the broader exercise-in-a-bottle narrative that keeps it in the popular imagination. Unlike the injectable gray-market peptides, its commercial life is driven by marketing concepts and research demand rather than a user-injected product.
How we got here
Irisin was named in 2012 by Pontus Bostrom and Bruce Spiegelman at Harvard, who identified it as the secreted C-terminal fragment of the pre-existing muscle protein FNDC5 (formerly catalogued under the gene names FRCP2 and PeP) and proposed it as the PGC1-alpha-driven signal that browns white fat. Within a year Harold Erickson (2013) challenged the finding, noting that the human FNDC5 gene carries a non-canonical ATA start codon that should sharply reduce full-length translation and that the detection antibodies were unvalidated, a critique sharpened by Albrecht et al. 2015 who argued most commercial-ELISA irisin readings are artifacts. The same year Spiegelman's group answered with antibody-free tandem mass spectrometry (Jedrychowski et al. 2015) detecting low-nanogram circulating irisin, and the 2021 Endocrine Reviews synthesis, co-authored by Erickson himself, settled on a middle position: irisin exists in human fluids but the ELISA literature is unreliable and human metabolic effects remain unproven. It has never been developed into an approved drug or a consumer supplement, and it is sold only as a research reagent.
Irisin was discovered in 2012 by Bostrom and colleagues in Spiegelman’s lab and was instantly celebrated as the exercise hormone that browns white fat. Within a few years it nearly collapsed, as the human gene’s mutated start codon and cross-reacting antibody kits led a 2015 paper to call it a myth. Mass-spectrometry work the same year confirmed it is real but circulates at very low levels, leaving its human importance unresolved. Research has since continued across metabolism, bone, brain and heart, much of it preclinical or correlational, while no drug emerged and boost-your-irisin marketing persisted.
- 2012Irisin is discovered and hailed as the fat-browning exercise hormone.
- 2013-2015Human gene and antibody-assay problems cast serious doubt on it.
- 2015A paper calls irisin a myth; mass spectrometry then confirms it is real but low-level.
- 2010s-2020sContested research continues across metabolism, bone and brain; no drug appears.
- ongoingBoost-your-irisin marketing persists, well ahead of the evidence.
The numbers behind the grade
- Type
- Muscle myokine
- Precursor
- FNDC5
- Claim
- Browns white fat
- Reality
- Real but low-level
- Status
- Contested
- Approved product
- None
The people taking it
The famous exercise hormone, one of the most-hyped metabolic discoveries of the 2010s, nearly debunked and then partly vindicated, real but of contested human importance, with no therapeutic product.
Irisin is more a research and marketing concept than a user population. Its relevant audiences are metabolic researchers studying it, consumers targeted by exercise-hormone and boost-your-irisin marketing, and metabolism- and fat-loss-minded people drawn to the idea, rather than the injecting users typical of gray-market peptides.
A research hormone and marketing concept around fat-browning and metabolism, studied broadly but contested in humans, with no therapeutic product and an unrealized exercise-in-a-bottle promise.
Set against the alternatives
The closest comparison is to GDF11, its sibling cautionary tale in this library: both are celebrated rejuvenation-or-exercise factors whose dramatic claims were undercut by measurement and antibody-specificity problems, then partly reconsidered, showing how hype and flawed detection can inflate a molecule’s reputation. Against exercise itself, the deflating point is that even if irisin is real, exercise reliably delivers the benefits while no irisin product replicates them. And within the broader hunt for exercise-in-a-molecule compounds, alongside MOTS-c and ERR-agonist research tools, irisin is one more candidate that has not produced an approved drug. Its strength is that it is a genuine, interesting molecule; its weakness is a reputation built well ahead of the evidence.
What we do not know
- Whether irisin’s very low physiological levels in humans do anything meaningful, the core unresolved question.
- Whether the fat-browning effect matters in adult humans, who have little brown fat.
- How to reconcile the contradictory human correlational data.
- Whether irisin is a marker of exercise rather than a mediator of its benefits.
What could change
Physiological relevanceThe key open question is whether real human irisin levels matter.Exercise-mimetic fieldIrisin remains part of the broader, unresolved search for exercise in a molecule.Marketing gapThe distance between boost-your-irisin claims and the evidence stays wide.No therapeuticThere is no irisin drug on the horizon.
Legal status
There is no approved irisin product and no real therapeutic; recombinant irisin exists only as a research reagent. Consumer access amounts to unvalidated boost-your-irisin supplement and exercise marketing. It is not a standard gray-market injectable and not a doping substance.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
There is no irisin drug to buy. Recombinant irisin is research-grade material, and boost-your-irisin supplements are unvalidated marketing. The reliable way to obtain the benefits attributed to irisin is exercise itself.
Recombinant irisin for research is expensive, and boost-your-irisin supplements vary in price, but there is no drug to price meaningfully. The honest path to irisin’s purported benefits, exercise, is free.
The only tangible supply is recombinant irisin from research-reagent suppliers; there is no therapeutic source because no drug exists.
Research reagentsRecombinant irisin is sold to laboratories for study, its main tangible supply.Supplement marketingThe boost-your-irisin concept is attached to exercise and supplement products.No therapeutic chainThere is no drug, so there is no therapeutic supply chain.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Irisin.
Nothing outstanding on this one.
Sources
Original discovery: PGC1-alpha drives muscle FNDC5 expression, cleaved and secreted as irisin, which browns white adipose tissue and induces UCP1 and thermogenesis in mice.
Foundational critique: irisin antibodies used in plasma detection lack validity, the recombinant protein tested in culture was severely truncated, and the degree of FNDC5 cleavage is unclear.
Erickson HP, 'Irisin and FNDC5 in retrospect', Adipocyte (2013)
Measurement controversy: commercial-ELISA irisin signal is largely an artifact of non-specific cross-reacting antibodies; irisin framed as 'a myth rather than an exercise-inducible myokine'.
Antibody-free confirmation: quantitative tandem mass spectrometry with heavy-isotope internal standards detects circulating human irisin (about 3.6 ng/mL sedentary, up to 4.3 ng/mL post-training) expressed from the non-canonical start codon.
PubMed record confirming the 2015 mass-spectrometry detection study and its antibody-independent method.
Comprehensive synthesis: human FNDC5 has a non-canonical ATA start codon and has substantially lost full-length translation; all ELISA-based irisin data are compromised by major methodical problems; rodent adipose-browning findings have little or no support in humans.
PMC full text of the 2021 Endocrine Reviews synthesis, documenting ATA start codon, six-orders-of-magnitude ELISA variance, and absence of human therapeutic evidence.
Commentary framing the field: measurement uncertainty and reproducibility problems leave the biology of circulating human irisin unsettled ('still chasing shadows').
'Irisin: Still chasing shadows', Molecular Metabolism (2020), PMC7033458
Independent editorial confirming that antibody-free mass spectrometry supports the existence of circulating irisin, while the ELISA-based literature remains disputed.
'Circulating irisin confirmed by mass spectrometry', Nature Reviews Endocrinology (2015)
Therapeutic evidence remains preclinical: systemic recombinant irisin effects (fracture healing) demonstrated in mice, not humans.
'Systemic Administration of Recombinant Irisin Accelerates Fracture Healing in Mice', PMC8509717
Human data on irisin are limited to exercise-association studies whose blood-level readouts depend on the disputed ELISA methodology.
The studies that matter
Bostrom et al, Cell2012
The discovery study: exercise and PGC1-alpha drive FNDC5 and irisin, which browned white fat and improved metabolism in mice, igniting the hype.
Human gene problem2013-2015
The human FNDC5 gene was found to carry an unusual mutated start codon, casting doubt on whether people produce functional irisin.
"Irisin a myth" paper2015
Analysis showed the commercial antibody kits used to measure irisin cross-reacted with unrelated proteins, with no bands of the expected size, challenging earlier human data.
Mass-spectrometry vindication2015
Rigorous mass-spectrometry confirmed irisin does circulate in humans and rises with exercise, but at very low levels.
Inconsistent human data2010s-2020s
Circulating irisin correlated inconsistently with metabolic measures, and FNDC5 turned out to be secreted by fat as well as muscle, complicating the picture.